AMRN - Dew or others: going to ask these two basic questions here rather than on the AMRN board, passions running a bit too high there. I'm still considering buying in, but waiting for the PPS to stabilize.
1. Perhaps over-simplifying, but am I correct in saying AMRN's main beef with the FDA is that while it agrees that Vascepa reduces triglycerides it will not accept this reduction as a validated surrogate for cardiovascular risk reduction?
2. Doesn't this refusal greatly affect all other companies working on triglyceride-reducing drugs? Specifically, I have a speculative position in ACST, they’re about to release PH II trial results for a krill-based product. If they’re ultimately going to run into the same roadblock, what’s the point?
TIA
All that is needed to make a happy life is within yourself, in your way of thinking. -Marcus Aurelius
